<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924361</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH Dementia Cohort Research</org_study_id>
    <nct_id>NCT04924361</nct_id>
  </id_info>
  <brief_title>Exploring Biomarkers in Age Stratified PUMCH Dementia Cohort</brief_title>
  <official_title>Exploring Biomarkers in Age Stratified PUMCH Dementia Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biomarkers are important for early and precise diagnosis of dementia. However, the causes of&#xD;
      dementia in different age are different. We designed an age stratified dementia cohort and&#xD;
      tried to explore biomarkers of different groups of dementia, incorporating neuropsychology,&#xD;
      multi-model neuroimaging, metabolics and proteomics based fluid biomarkers as well as genetic&#xD;
      biomarkers. Autopsy after clinical follow up help to verify the biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline data collection and cohort establishing: Detailed clinical information including&#xD;
      demographic data, clinical history, past history and physical examination are collected.&#xD;
      Formatted neuropsychological battery is used in all patients, including screening tests&#xD;
      (MMSE, MoCA-PUMCH, ADL, HAD) and domain specific evaluation (Memory, executive function,&#xD;
      visual spatial, calculation, language). Samples including serum, CSF, urine, skin, saliva are&#xD;
      stored. Every patient is followed up every 6 months. Autopsy brain tissue will be collected&#xD;
      if patients died.&#xD;
&#xD;
      Multi-model neuroimaging evaluation: Structure and functional brain 3T-MRI; 7T-MRI； PET-CT&#xD;
      including FDG, Aβ（18F-AV45）,tau（18F-THK5317, 18F-T807）; EEG&#xD;
&#xD;
      Multi-omics biomarkers research:&#xD;
&#xD;
      CSF AD biomarkers (Aβ40,42, ptau181, ttau, NfL, Neurogranin), comparison of different&#xD;
      methods, including ELISA, Electrochemical, Mass Spectroscopy. The standardization of CSF&#xD;
      biomarkers analysis in China.&#xD;
&#xD;
      Exploring new fluid biomarkers: CSF and Urine proteomics; CSF and serum glycomics and&#xD;
      metabolomics. To explore new biomarkers in differentiation of different causes of dementia,&#xD;
      age onset and prognosis of dementia.&#xD;
&#xD;
      Genetic biomarkers evaluation: including pathogenic gene mutation panel examination and WES.&#xD;
&#xD;
      Data analysis and biomarkers evaluation: Dementia patients are stratified based on age onset,&#xD;
      cause of dementia, cognition severity, effect of therapy, prognosis. Identify multi-omics&#xD;
      biomarkers in different groups. Comparing the relationships between biomarkers and clinical&#xD;
      presentations as well as neuroimaging. Autopsy based accurate diagnosis help further defining&#xD;
      biomarkers.&#xD;
&#xD;
      Acquiring stratified biomarkers with high sensitivity and specificity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incorporating age stratified biomarkers into the diagnosis of dementia</measure>
    <time_frame>Through study completion,an average of 5 years</time_frame>
    <description>Comparing the relationships between biomarkers and clinical presentations as well as neuroimaging. Incorporate biomarkers into the accurate and early diagnosis of dementia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establishing dementia cohort including detailed clinical information, fluid samples and brain bank</measure>
    <time_frame>Through study completion,an average of 5 years</time_frame>
    <description>Detailed clinical information including demographic data, clinical history, past history and physical examination are collected. Formatted neuropsychological battery is used in all patients, including screening tests (MMSE, MoCA-PUMCH, ADL, HAD) and domain specific evaluation (Memory, executive function, visual spatial, calculation, language). Samples including serum, CSF, urine, skin, saliva are stored. Every patient is followed up every 6 months. Autopsy brain tissue will be collected if patients died after informed consent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploring 5-10 kinds of age stratified biomarkers, including neuropsychology, neuroimaging, fluid biomarkers and genetic biomarkers</measure>
    <time_frame>Through study completion,an average of 5 years</time_frame>
    <description>Find out age stratified biomarkers with high sensitivity and specificity, including neuropsychology, Multi-model neuroimaging, Multi-omics fluid biomarkers and genetic biomarkers</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Dementia</condition>
  <condition>Dementia, Vascular</condition>
  <condition>Dementia Frontal</condition>
  <condition>Dementia, Mixed</condition>
  <condition>Dementia Alzheimers</condition>
  <condition>Dementia With Lewy Bodies</condition>
  <arm_group>
    <arm_group_label>Early onset dementia</arm_group_label>
    <description>Dementia patients with onset age lower than 65y/o</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late onset dementia</arm_group_label>
    <description>Dementia patients with onset age between 65y/o and 85y/o</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oldest old dementia</arm_group_label>
    <description>Dementia patients with onset age older than 85y/o</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive normal control</arm_group_label>
    <description>cognitive normal control</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        We included age stratified dementia (early onset, late onset, oldest old) , including AD,&#xD;
        FTD,VaD, DLB and mixed dementia. Also we include cognitive normal controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Neurodegenerative dementia diagnosis based on 2011 NIA-AA criteria of Dementia&#xD;
&#xD;
          -  Fixed care giver and can follow up regularly&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not demented, including MCI&#xD;
&#xD;
          -  Systemic severe diseases and severe vision or hearing problem effecting follow up and&#xD;
             neuropsychological evaluation&#xD;
&#xD;
          -  Without fixed care giver&#xD;
&#xD;
          -  Reject informed consent&#xD;
&#xD;
          -  Expected life shorter than 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Gao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chenhui Mao, Doctor</last_name>
    <phone>+86018611895308</phone>
    <email>maochenhui@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chenhui Mao, Doctor</last_name>
      <email>maochenhui@pumch.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jing Gao, Doctor</last_name>
      <email>gj107@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kuruppu DK, Matthews BR. Young-onset dementia. Semin Neurol. 2013 Sep;33(4):365-85. doi: 10.1055/s-0033-1359320. Epub 2013 Nov 14. Review.</citation>
    <PMID>24234358</PMID>
  </reference>
  <reference>
    <citation>Rabinovici GD. Late-onset Alzheimer Disease. Continuum (Minneap Minn). 2019 Feb;25(1):14-33. doi: 10.1212/CON.0000000000000700. Review.</citation>
    <PMID>30707185</PMID>
  </reference>
  <reference>
    <citation>Yang Z, Slavin MJ, Sachdev PS. Dementia in the oldest old. Nat Rev Neurol. 2013 Jul;9(7):382-93. doi: 10.1038/nrneurol.2013.105. Epub 2013 Jun 4. Review.</citation>
    <PMID>23732531</PMID>
  </reference>
  <reference>
    <citation>Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Review.</citation>
    <PMID>29653606</PMID>
  </reference>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>September 10, 2022</last_update_submitted>
  <last_update_submitted_qc>September 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>gaojing</investigator_full_name>
    <investigator_title>Professor, Department of Neurology</investigator_title>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>Diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

